Amgen reports positive lung cancer trial results for Imdelltra combined with checkpoint inhibitor
read at Endpoints ↗Positive readoutPositive
Amgen announced that its T-cell engager candidate Imdelltra, when used together with a checkpoint inhibitor, showed a clinical benefit in patients with advanced lung cancer.
The trial data indicated that the combination extended overall survival compared with standard therapy, marking a significant milestone for the company's immunotherapy platform.
The results are expected to advance Imdelltra toward later-stage development and could broaden treatment options for a disease with high unmet need.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Amgen’s T cell engager notches new major lung cancer victory”
read at Endpoints ↗80 words · retrieved Sep 8
comments(0)
5-min edit window · permanent after that